Phase 1 Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immune Function Effects, and Efficacy of Multiple Doses of CP-675,206 in Patients With Advanced Melanoma, and Phase 2, Open Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Regimens of CP-675,206 in Patients With Advanced Melanoma.

Trial Profile

Phase 1 Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immune Function Effects, and Efficacy of Multiple Doses of CP-675,206 in Patients With Advanced Melanoma, and Phase 2, Open Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Regimens of CP-675,206 in Patients With Advanced Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Sep 2015

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 10 Sep 2015 Retrospective analysis of this study and 3 other studies [See CTP700023738, CTP700006688 , study A3671001] were published in the European Journal of Cancer.
    • 05 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.(NCT00086489).
    • 05 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.(NCT00086489).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top